Personalised skin cancer vaccine cuts risk of death or recurrence by 42% in trial
Health · Sunday, November 1, 2026 · 2 sources

Personalised skin cancer vaccine cuts risk of death or recurrence by 42% in trial

A global two-year clinical trial involving more than 1,000 patients whose tumours had been removed found that a personalised vaccine, given alongside an immunotherapy drug, reduced the risk of death or skin cancer returning by 42%. Around two-thirds of participants received the experimental vaccine, made using cells from their own tumours.

Bottom line — The trial tested the vaccine in patients after tumour removal, alongside an immunotherapy drug.

Go deeper 3

  1. All trial participants received a widely used immunotherapy drug.

  2. The vaccine was developed using cells from each patient's own tumour.

  3. The BBC reports the trial lasted two years and involved more than 1,000 patients.

Read the reporting 2

dstld. Your daily news summary designed to surface the news that matters from a European perspective. Curated by humans, summarized by AI - always with links back to the original reporting.

Links · Contact
Popular topics · WorldEuropeGamesAI
Last generated: Nov 1, 5:51 PM UTC by wreetco

dstld. Your daily news summary designed to surface the news that matters from a European perspective. Curated by humans, summarized by AI - always with links back to the original reporting.

Links · Contact
Popular topics · WorldEuropeGamesAI
Last generated: Nov 1, 5:51 PM UTC by wreetco